Class of 2025
For unrivaled investigations leading to the understanding of oncogenic pathways, including the Hedgehog and Wnt signaling pathways, and for spearheading drug development, including vismodegib, the first Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma.
*Full-length biography in development
[Institutional affiliations listed for Fellows reflect those held at the time of their induction into the AACR Academy.]